Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-10
2000-09-19
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142278, 5142368, 514314, 514326, 514342, 540 1, 540603, 544 584, 544133, 544369, 546156, 5462697, 546280, 548187, 548204, C07D27724, A61K 31427
Patent
active
061213004
ABSTRACT:
The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
REFERENCES:
patent: 4492450 (1985-01-01), Cassal et al.
patent: 4558046 (1985-12-01), Doria et al.
patent: 4609660 (1986-09-01), Doria et al.
patent: 4609670 (1986-09-01), Dominianni et al.
patent: 4683312 (1987-07-01), Dominianni et al.
patent: 4886814 (1989-12-01), Reiffen et al.
patent: 4956370 (1990-09-01), Ippen et al.
patent: 5128351 (1992-07-01), Wissner
patent: 5219852 (1993-06-01), Reiffen et al.
patent: 5225425 (1993-07-01), Wissner
patent: 5230998 (1993-07-01), Neurath et al.
patent: 5240950 (1993-08-01), Sohda et al.
patent: 5266578 (1993-11-01), Raddatz et al.
patent: 5302608 (1994-04-01), Sohda et al.
patent: 5350759 (1994-09-01), Wissner
patent: 5432189 (1995-07-01), Wissner
patent: 5449680 (1995-09-01), Solomon et al.
patent: 5457205 (1995-10-01), Reiffen et al.
patent: 5500436 (1996-03-01), Schonafinger et al.
patent: 5532257 (1996-07-01), Hase et al.
patent: 5604225 (1997-02-01), Reiffen et al.
patent: 5665748 (1997-09-01), Sohda et al.
patent: 5679704 (1997-10-01), Schonafinger et al.
patent: 5700819 (1997-12-01), Aotsuka et al.
Tsuge Bull Chem Soc Japan 58, 3137-57, Nov. 1985.
Tamura et al., Novel Syntheses of Thiazolo[3,2-b]-s-triazoles, J. Heterocyclic Chem. 10: 947-951, 1973.
Potts et al., Cycloaddition of N-Iminothiazolium Ylides with Acetylenic Dipolarophiles. Formation of Pyrazoles.sup.1, J. Org. Chem. vol. 42, No. 9, 1977 pp. 1648-1649.
Potts et al., Bridgehead Nitrogen Systems. X. Cycloadditions with Thiazolium N-Ylides.sup.1, J. Org. Chem. vol. No. 2, pp. 187-191, 1976.
Archer et al., An Attempt to Apply Lethal Synthesis to the Design of Chemotherapeutic Agents. Fluorinated 5.beta.-(Hydoxyethyl)-4-methylthiazoles, J. of Medicinal Chemistry, vol. 22, No. 3, 1979.
Tsuge et al., Chemistry Letters. Formation of Novel Cage Compounds Via Endo-[3+2] Cycloadducts Between Thiazolium N-Methylides and Methylenecyclopropenes, vol. 5, pp. 711-714, 1982.
Hirano et al., New Aspects of the 1,3-Dipolar Cycloaddition of Thiazolium N-Imines with Dimethyl Acetylenedicarboxylate (DMAD), Chem. Pharm. Bull., vol. 32, 1984.
Dominianni et al., J. of Medicinal Chemistry, Oral Hypoglycemic Agents. Discovery and Structure--Activity Relationships of Phenacylimidazolium Halides, 32:2301-2306, 1989.
Gandasegui, MT et al., Heterocycles, Synthisis of New Disubstituted Azolium Ylides, 31:(10): 1801-9, 1990.
Aldrich Catalog Handbook of Fine Chemicals, 1992-1993, pp. 134, 257, 505, 594.
Singh et al., Tetrahedron, Aqueous Base Induced Selective Transformations of 3-(2-Oxoalkyl) Thiazolium Cations, 48:(22) 4545-50, 1992.
Kumar et al., J. Medicinal Chemistry, Synthesis of 2,4-Disubstituted Thiazoles and Selenazoles as Potential Antitumor and Antifilarial Agents: 1. Methyl 4-(isothiocyanatomethyl)thiazole-2-carbamates,-selenazole-2-carbamtes, and Related Derivatives, 36:3843-3848, 1993.
Hays et al., Journal of Pharmaceutical Sciences, Substituted 2-Benzothiazolamines as Sodium Flux Inhibitors: Quantitative Structure-Activity Relationships and Anticonvulsant Activity, vol. 83, No. 10, 1994.
Cerami Anthony
Egan John J.
Fang Sheng-Ding
Rho Taikyun
Ulrich Peter
LandOfFree
Reversing advanced glycosylation cross-links using heterocyclic- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversing advanced glycosylation cross-links using heterocyclic-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversing advanced glycosylation cross-links using heterocyclic- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073640